Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region
- 13 November 2006
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 29 (1), 47-51
- https://doi.org/10.1002/hed.20462
Abstract
Background. The aim of this phase II study was to evaluate the antitumor activity and toxicity of a non-platin–containing regimen with paclitaxel and capecitabine. Methods. Fifty patients with recurrent or disseminated squamous cell carcinoma were included in the study. The treatment consisted of paclitaxel 175 mg/m2 once every third week and capecitabine 825 mg/m2 per oral (p.o.) twice daily (bid) for 2 weeks. Results. The overall response rate according to the World Health Organization (WHO) criteria was 42%. Two patients had a complete response (CR), 19 patients had a partial response (PR), 14 patients had no change (NC), 12 patients had progressive disease (PD), and 3 patients were not evaluable (NE). The median survival time was 8 months. Toxicity was very moderate. Only 10% of 315 delivered treatments had to be given in reduced dose or postponed for a week or more. Conclusions. The toxicity was low and manageable. The overall response rate was comparable to the commonly used cisplatin/5-fluorouracil regimen. © 2006 Wiley Periodicals, Inc. Head Neck 2007Keywords
This publication has 15 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- XELODA® AND TAXOTERE®: A REVIEW OF THE DEVELOPMENT OF THE COMBINATION FOR USE IN METASTATIC BREAST CANCERInternational Journal Of Clinical Practice, 2003
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III StudyJournal of Clinical Oncology, 2001
- A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patientsAnnals Of Oncology, 2001
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEuropean Journal Of Cancer, 1998
- Single agent paclitaxel in advanced squamous cell head and neck carcinomaEuropean Journal Of Cancer, 1996
- Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials.Journal of Clinical Oncology, 1996
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958